-
1.发明申请
公开(公告)号：WO2005058890A3
公开(公告)日：2005-08-18
申请号：PCT/EP2004053373
申请日：2004-12-09
Applicant: SOLVAY PHARM GMBH , MENTZEL MATTHIAS , REICHE DANIA B , BRUCKNER REINHARD , DAVID SAMUEL , VAN STEEN BARTHOLOMEUS J , SCHON UWE , JASSERAND DANIEL , PREUSCHOFF ULF
Inventor： MENTZEL MATTHIAS , REICHE DANIA B , BRUCKNER REINHARD , DAVID SAMUEL , VAN STEEN BARTHOLOMEUS J , SCHON UWE , JASSERAND DANIEL , PREUSCHOFF ULF
IPC: A61K31/438 , A61K31/4747 , A61P9/06 , A61P9/12 , A61P29/00 , C07D221/00 , C07D233/00 , C07D471/10 , C07D487/08
CPC classification number: C07D471/10
Abstract: The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.
Abstract translation: 本发明涉及作为人ORL1（伤害感受肽）受体激动剂的一组水溶角质醇衍生物。 本发明还涉及这些化合物的制备，含有药理学活性量的至少一种这些新型水溶黄酚醇衍生物作为活性成分的药物组合物，以及这些药物组合物用于治疗其中 ORL1受体参与。 本发明涉及通式（1）的化合物，其中符号具有在说明书中给出的含义。
-
公开(公告)号：NO20063138A
公开(公告)日：2006-09-06
申请号：NO20063138
申请日：2006-07-06
Applicant: SOLVAY PHARM GMBH
Inventor： MENTZEL MATTHIAS , REICHE DANIA B , BRUCKNER REINHARD , DAVID SAMUEL , STEEN BARTHOLOMEUS J VAN , SCHON UWE , JASSERAND DANIEL , PREUSCHOFF ULF
IPC: C07D471/10 , A61K31/4747 , C07D487/08
CPC classification number: C07D471/10
-
公开(公告)号：AU2007211475A1
公开(公告)日：2007-08-09
申请号：AU2007211475
申请日：2007-02-01
Applicant: SOLVAY PHARM GMBH
Inventor： BRUCKNER REINHARD , PREUSCHOFF ULF , JAUNZEMS JANIS , BENSON WERNER , ATTALI AMOS , SANN HOLGER , MENTZEL MATTHIAS , ADOLFS MARTINUS , FIRNGES MICHAEL , JASSERAND DANIEL
IPC: C07D211/66 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/445 , C07D211/58 , C07D211/62 , C07D295/14 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12
-
公开(公告)号：BRPI0417161A
公开(公告)日：2007-03-06
申请号：BRPI0417161
申请日：2004-12-09
Applicant: SOLVAY PHARM GMBH
Inventor： MENTZEL MATTHIAS , REICHE DANIA B , BRUECKNER REINHARD , DAVID SAMUEL , STEEN BARTHOLOMEUS J VAN , UWE SCHOEN , JASSERAND DANIEL , PREUSCHOFF ULF
IPC: A61K31/438 , A61K31/4747 , A61P9/06 , A61P9/12 , A61P29/00 , C07D221/00 , C07D233/00 , C07D471/10 , C07D487/08
Abstract: The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.
-
公开(公告)号：NO20063138L
公开(公告)日：2006-09-06
申请号：NO20063138
申请日：2006-07-06
Applicant: SOLVAY PHARM GMBH
Inventor： MENTZEL MATTHIAS , REICHE DANIA B , BRUCKNER REINHARD , DAVID SAMUEL , STEEN BARTHOLOMEUS J VAN , SCHON UWE , JASSERAND DANIEL , PREUSCHOFF ULF
IPC: C07D471/10 , A61K31/4747 , C07D487/08
Abstract: The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.
-
Patent Agency Ranking
公开(公告)号：CA2547633A1
公开(公告)日：2005-06-30
申请号：CA2547633
申请日：2004-12-09
Applicant: SOLVAY PHARM GMBH
Inventor： JASSERAND DANIEL , BRUCKNER REINHARD , VAN STEEN BARTHOLOMEUS J , REICHE DANIA B , SCHON UWE , MENTZEL MATTHIAS , PREUSCHOFF ULF , DAVID SAMUEL
IPC: C07D471/10 , A61K31/438 , A61K31/4747 , A61P9/06 , A61P9/12 , A61P29/00 , C07D221/00 , C07D233/00 , C07D487/08
Abstract: The invention relates to a group of hydronopol derivatives which are agonist s on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the descriptio n.
-
公开(公告)号：UA84896C2
公开(公告)日：2008-12-10
申请号：UAA200607374
申请日：2004-12-09
Applicant: SOLVAY PHARM GMBH
Inventor： MENTZEL MATTHIAS , REICHE DANIA B , BRUCKNER REINHARD , DAVID SAMUEL , VAN STEEN BARTHOLOMEUS J , SCHON UWE , JASSERAND DANIEL , PREUSCHOFF ULF
IPC: C07D471/00 , A61K31/438 , A61K31/4747 , A61P9/06 , A61P9/12 , A61P29/00 , C07D221/00 , C07D233/00 , C07D471/10 , C07D487/08
Abstract: Изобретениекасаетсягруппыпроизводныхгидронопола, которыеявляютсяагонистамичеловеческихрецепторов ORL1 (ноцицептина).Изобретениетакжекасаетсяспособовполученияэтихсоединений, фармацевтическихкомпозиций, которыесодержатфармакологическиактивноеколичество, покрайнеймере, одногоизэтихновыхпроизводныхгидронополакакдействующеговещества, атакжепримененияэтихфармацевтическихкомпозицийдлялечениярасстройств, связанныхс рецепторами ORL1.Изобретениекасаетсясоединенийобщейформулы (1),гдерадикалыимеютзначения, которыеприведеныв описании.
-
公开(公告)号：CA2641817A1
公开(公告)日：2007-08-09
申请号：CA2641817
申请日：2007-02-01
Applicant: SOLVAY PHARM GMBH
Inventor： JASSERAND DANIEL , PREUSCHOFF ULF , MCCREARY ANDREW CHRISTOPHER , MENTZEL MATTHIAS , JAUNZEMS JANIS , SMID PETER , SCHON UWE , BENSON WERNER , ADOLFS MARTINUS , REICHE DANIA , SANN HOLGER , BRUCKNER REINHARD , FIRNGES MICHAEL , ATTALI AMOS
IPC: C07D211/66 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/445 , C07D211/58 , C07D211/62 , C07D295/14 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12
-
公开(公告)号：AR046756A1
公开(公告)日：2005-12-21
申请号：ARP040104561
申请日：2004-12-07
Applicant: SOLVAY PHARM GMBH
Inventor： MENTZEL MATTHIAS , REICHE DANIA , BRUCKNER REINHARD , DAVID SAMUEL , STEEN BARTHOLOMEUS JOHANNES VAN , SCHON UWE , JASSERAND DANIEL , PREUSCHOFF ULF
IPC: A61K31/438 , A61K31/4747 , A61P9/06 , A61P9/12 , A61P29/00 , C07D221/00 , C07D233/00 , C07D471/10 , C07D487/08 , A61P10/08
Abstract: Se refiere a un grupo de derivados de hidronopol que son agonistas de receptores ORL1 humanos (nociceptina). También se refiere a la preparación de estos compuestos, a composiciones farmacéuticas que contienen como ingrediente activo una cantidad farmacológicamente activa de al menos uno de estos nuevos derivados de hidronopol, como así también al uso de estas composiciones farmacéuticas para el tratamiento de trastornos en los cuales están implicados receptores ORL1. Se refiere a compuestos de fórmula general 1 donde los símbolos tienen los significados dados en la memoria descriptiva.
-
公开(公告)号：AU2004298436A1
公开(公告)日：2005-06-30
申请号：AU2004298436
申请日：2004-12-09
Applicant: SOLVAY PHARM GMBH
Inventor： MENTZEL MATTHIAS , STEEN BARTHOLOMEUS J VAN , DAVID SAMUEL , JASSERAND DANIEL , REICHE DANIA B , PREUSCHOFF ULF , BRUCKNER REINHARD , SCHON UWE
IPC: C07D471/10 , A61K31/438 , A61K31/4747 , A61P9/06 , A61P9/12 , A61P29/00 , C07D221/00 , C07D233/00 , C07D487/08
Abstract: The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.022 seconds)
